Treating tobacco dependence

Review of the best and latest treatment options

Jon Owen Ebbert, Amit Sood, James Taylor Hays, Lowell C. Dale, Richard D. Hurt

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Globally, an estimated 85% of lung cancer in men and 47% of lung cancer in women is attributable to tobacco smoking. Tobacco dependence treatment remains the most cost-effective way to prevent morbidity and mortality from lung cancer. Several effective pharmacotherapies are available to treat tobacco dependence. However, the long-term effectiveness of these treatments has been limited because the majority of smokers who attempt to stop smoking eventually relapse. Approaching the treatment of tobacco use and dependence as a chronic disease and the development of innovative drug therapies offer new hope for the treatment of tobacco-dependent patients. The diagnosis of lung cancer provides a teachable moment to motivate patients to attempt tobacco abstinence on which clinicians should capitalize. We review the currently available pharmacologic approaches to the treatment of tobacco dependence.

Original languageEnglish (US)
Pages (from-to)249-256
Number of pages8
JournalJournal of Thoracic Oncology
Volume2
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Tobacco Use Disorder
Lung Neoplasms
Tobacco
Hope
Smoking
Drug Therapy
Investigational Therapies
Tobacco Use
Therapeutics
Chronic Disease
Morbidity
Costs and Cost Analysis
Recurrence
Mortality

Keywords

  • Bupropion
  • Drug therapy
  • Nicotine
  • Smoking cessation
  • Tobacco use cessation
  • Varenicline

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Treating tobacco dependence : Review of the best and latest treatment options. / Ebbert, Jon Owen; Sood, Amit; Hays, James Taylor; Dale, Lowell C.; Hurt, Richard D.

In: Journal of Thoracic Oncology, Vol. 2, No. 3, 03.2007, p. 249-256.

Research output: Contribution to journalArticle

Ebbert, Jon Owen ; Sood, Amit ; Hays, James Taylor ; Dale, Lowell C. ; Hurt, Richard D. / Treating tobacco dependence : Review of the best and latest treatment options. In: Journal of Thoracic Oncology. 2007 ; Vol. 2, No. 3. pp. 249-256.
@article{5d89fb9394f24e4d9912136e2afbcdd7,
title = "Treating tobacco dependence: Review of the best and latest treatment options",
abstract = "Globally, an estimated 85{\%} of lung cancer in men and 47{\%} of lung cancer in women is attributable to tobacco smoking. Tobacco dependence treatment remains the most cost-effective way to prevent morbidity and mortality from lung cancer. Several effective pharmacotherapies are available to treat tobacco dependence. However, the long-term effectiveness of these treatments has been limited because the majority of smokers who attempt to stop smoking eventually relapse. Approaching the treatment of tobacco use and dependence as a chronic disease and the development of innovative drug therapies offer new hope for the treatment of tobacco-dependent patients. The diagnosis of lung cancer provides a teachable moment to motivate patients to attempt tobacco abstinence on which clinicians should capitalize. We review the currently available pharmacologic approaches to the treatment of tobacco dependence.",
keywords = "Bupropion, Drug therapy, Nicotine, Smoking cessation, Tobacco use cessation, Varenicline",
author = "Ebbert, {Jon Owen} and Amit Sood and Hays, {James Taylor} and Dale, {Lowell C.} and Hurt, {Richard D.}",
year = "2007",
month = "3",
doi = "10.1097/JTO.0b013e318031bca4",
language = "English (US)",
volume = "2",
pages = "249--256",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - Treating tobacco dependence

T2 - Review of the best and latest treatment options

AU - Ebbert, Jon Owen

AU - Sood, Amit

AU - Hays, James Taylor

AU - Dale, Lowell C.

AU - Hurt, Richard D.

PY - 2007/3

Y1 - 2007/3

N2 - Globally, an estimated 85% of lung cancer in men and 47% of lung cancer in women is attributable to tobacco smoking. Tobacco dependence treatment remains the most cost-effective way to prevent morbidity and mortality from lung cancer. Several effective pharmacotherapies are available to treat tobacco dependence. However, the long-term effectiveness of these treatments has been limited because the majority of smokers who attempt to stop smoking eventually relapse. Approaching the treatment of tobacco use and dependence as a chronic disease and the development of innovative drug therapies offer new hope for the treatment of tobacco-dependent patients. The diagnosis of lung cancer provides a teachable moment to motivate patients to attempt tobacco abstinence on which clinicians should capitalize. We review the currently available pharmacologic approaches to the treatment of tobacco dependence.

AB - Globally, an estimated 85% of lung cancer in men and 47% of lung cancer in women is attributable to tobacco smoking. Tobacco dependence treatment remains the most cost-effective way to prevent morbidity and mortality from lung cancer. Several effective pharmacotherapies are available to treat tobacco dependence. However, the long-term effectiveness of these treatments has been limited because the majority of smokers who attempt to stop smoking eventually relapse. Approaching the treatment of tobacco use and dependence as a chronic disease and the development of innovative drug therapies offer new hope for the treatment of tobacco-dependent patients. The diagnosis of lung cancer provides a teachable moment to motivate patients to attempt tobacco abstinence on which clinicians should capitalize. We review the currently available pharmacologic approaches to the treatment of tobacco dependence.

KW - Bupropion

KW - Drug therapy

KW - Nicotine

KW - Smoking cessation

KW - Tobacco use cessation

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=34247108185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247108185&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318031bca4

DO - 10.1097/JTO.0b013e318031bca4

M3 - Article

VL - 2

SP - 249

EP - 256

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -